Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tainted ED

This article was originally published in The Tan Sheet

Executive Summary

New York-based EG Labs voluntarily recalls all lots of its Viapro 375mg capsules after FDA found an undisclosed ingredient - thiomethisosildenafil, an analog of an active ingredient in prescription erectile dysfunction drugs. The capsules were sold by retailers nationwide and were packaged in one- and two-count blister packs and 10-count bottles. The product has not been sold since March 2008, the firm says. In another recent case, FDA seized $74,000 in mislabeled erectile dysfunction supplements from SEI Pharmaceuticals (1"The Tan Sheet" July 28, 2008, p. 15)...

You may also be interested in...

FDA Maintains Pressure Against Adulterated ED Supplements

FDA says its seizure of $74,000 in mislabeled erectile dysfunction supplements from SEI Pharmaceuticals July 24 demonstrates the steps the agency will take when a company fails to heed a warning about an allegedly adulterated product

Device Week, 27 February 2020 – The Risky Business Of Bringing ISO 14971:2019 Into Quality Systems

On this week’s podcast, executive editor Shawn M. Schmitt shares expert tips and advice on how device makers can integrate the recently revised international risk management standard ISO 14971 into their quality systems.

Start-Up Snapshot: Alpha Tau Hopes For A Breakthrough In Radiotherapy

Alpha Tau is looking to change the global radiation therapy paradigm. The Israeli start-up is developing Alpha DaRT, a novel technology for delivering alpha radiation for local tumor destruction.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts